Contrast study of assessment of Her2 gene by fluorescence in situ hybridization and immunohistochemistry technique in neoadjuvant chemotherapy breast cancer patients
10.3760/cma.j.issn.1008-1372.2012.01.003
- VernacularTitle:FISH及IHC法检测乳腺癌新辅助化疗前后HER2状况的对比研究
- Author:
Juan HUANG
;
Xueli HU
;
Jian HAI
;
Feiyu CHEN
;
Ting XIA
;
Yaning HE
;
Lili TANG
- Publication Type:Journal Article
- Keywords:
In situ hybridization,fluorescence;
Immunohistochemistry;
Receptor,erbB-2/ME;
Breast neoplasms/DT/ME;
Chemotherapy,adjuvant
- From:
Journal of Chinese Physician
2012;14(1):5-8
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo evaluate the consistency of HER2 gene status before and after neoadjuvant chemotherapy in breast cancer by FISH (fluorescence in situ hybridization) and IHC (immunohistochemistry) techniques,and analyze the factor of the difference in the result and the feasibility of HER2 gene tested by FISH in the neoadjuvant chemotherapy breast cancer patients.Methods FISH and IHC for HER2 gene expression status was performed on the archival paraffin-embedded sections of breast cancer tissues before and after neoadjuvant chemotherapy from 135 Chinese female patients,x2 test of paired comparison of enumeration data and Kappa analysis were used to compare the difference and consistency of this two techniques.ResultsThe detection rate of HER2 status in punctured cancer tissues before neoadjuvant chemotherapy by FISH and HER2 did not show statistical difference in our research while the opposite result were showed in cancer tissues after neoadjuvant chemotherapy.Moreover,the two techniques of HER2 test were less concordant in patients accepted taxanes neoadjuvant chemotherapy than CAF treatment.ConclusionsThe consistency of FISH and IHC techniques of cancer tissues before neoadjuvant chemotherapy gained advantage compared to the ones after neoadjuvant chemotherapy.Patients received neoadjuvant chemotherapy especially taxanes should take the test of HER2 gene status by FISH technique.
